Ivana Gojo

Associate Professor

19992018
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Fingerprint is based on mining the text of the experts' scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 24 Similar Profiles
Acute Myeloid Leukemia Medicine & Life Sciences
Leukemia Medicine & Life Sciences
Cytarabine Medicine & Life Sciences
alvocidib Medicine & Life Sciences
Consolidation Chemotherapy Medicine & Life Sciences
tipifarnib Medicine & Life Sciences
Bone Marrow Medicine & Life Sciences
Cyclophosphamide Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1999 2018

A multi-center phase i trial of ipilimumab in patients with myelodysplastic syndromes following hypomethylating agent failure

Zeidan, A. M., Knaus, H. A., Robinson, T., Towlerton, A. M. H., Warren, E. H., Zeidner, J. F., Blackford, A. L., Duffield, A. S., Rizzieri, D., Frattini, M. G., Levy, Y. M., Schroeder, M. A., Ferguson, A., Sheldon, K. E., Dezern, A., Gojo, I., Gore, S. D., Streicher, H., Luznik, L. & Smith, B. D., Aug 1 2018, In : Clinical Cancer Research. 24, 15, p. 3519-3527 9 p.

Research output: Contribution to journalArticle

Myelodysplastic Syndromes
ipilimumab
Inducible T-Cell Co-Stimulator Protein
Bone Marrow
T-Lymphocytes

Early identification of intracranial hemorrhage using a predictive nomogram

Chandler, F. L., Kane, J., Blackford, A. L., Weinberger, M., Wagner, K. C., Gojo, I., Cohen, M. & Apostol, C., Mar 1 2018, In : Oncology Nursing Forum. 45, 2, p. 177-186 10 p.

Research output: Contribution to journalArticle

Nomograms
Intracranial Hemorrhages
Blood Pressure
Signs and Symptoms
Partial Thromboplastin Time

Final results of a randomized multicenter phase II study of alvocidib, cytarabine, and mitoxantrone versus cytarabine and daunorubicin (7 + 3) in newly diagnosed high-risk acute myeloid leukemia (AML)

Zeidner, J. F., Foster, M. C., Blackford, A. L., Litzow, M. R., Morris, L. E., Strickland, S. A., Lancet, J. E., Bose, P., Levy, M. Y., Tibes, R., Gojo, I., Gocke, C., Rosner, G., Little, R. F., Wright, J. J., Doyle, L. A., Smith, B. D. & Karp, J., Sep 1 2018, In : Leukemia Research. 72, p. 92-95 4 p.

Research output: Contribution to journalLetter

alvocidib
Mitoxantrone
Daunorubicin
Cytarabine
Acute Myeloid Leukemia

A phase 1 study of the PARP inhibitor veliparib in combination with temozolomide in acute myeloid leukemia

Gojo, I., Beumer, J. H., Pratz, K., McDevitt, M. A., Baer, M. R., Blackford, A. L., Smith, B. D., Gore, S. D., Carraway, H. E., Showel, M., Levis, M. J., Dezern, A., Gladstone, D., Ji, J. J., Wang, L., Kinders, R. J., Pouquet, M., Ali-Walbi, I., Rudek-Renaut, M., Poh, W. & 5 othersHerman, J. G., Karnitz, L. M., Kaufmann, S. H., Chen, A. & Karp, J., Feb 1 2017, In : Clinical Cancer Research. 23, 3, p. 697-706 10 p.

Research output: Contribution to journalArticle

temozolomide
Acute Myeloid Leukemia
Methylation
Phosphorylation
Polymers

A phase I study of topotecan, carboplatin and the PARP inhibitor veliparib in acute leukemias, aggressive myeloproliferative neoplasms, and chronic myelomonocytic leukemia

Pratz, K., Rudek-Renaut, M., Gojo, I., Litzow, M. R., McDevitt, M. A., Ji, J., Karnitz, L. M., Herman, J. G., Kinders, R. J., Smith, B. D., Gore, S. D., Carraway, H. E., Showel, M., Gladstone, D., Levis, M. J., Tsai, H. L., Rosner, G., Chen, A., Kaufmann, S. H. & Karp, J., Feb 15 2017, In : Clinical Cancer Research. 23, 4, p. 899-907 9 p.

Research output: Contribution to journalArticle

Leukemia, Myelomonocytic, Chronic
Topotecan
Carboplatin
Leukemia
Neoplasms